APA (7th ed.) Citation

J, M., C, B., J, T., LS, W., S, S., & M, G. (2025). Revisiting the use of capecitabine in the era of immunotherapy: Efficacy as second-line and later therapy in recurrent/metastatic head and neck squamous cell carcinoma. Oral oncology, 164, 107293. https://doi.org/10.1016/j.oraloncology.2025.107293

Chicago Style (17th ed.) Citation

J, Ma, Brooks C, Tasoulas J, Wind LS, Sheth S, and Gwynn M. "Revisiting the Use of Capecitabine in the Era of Immunotherapy: Efficacy as Second-line and Later Therapy in Recurrent/metastatic Head and Neck Squamous Cell Carcinoma." Oral Oncology 164 (2025): 107293. https://doi.org/10.1016/j.oraloncology.2025.107293.

MLA (9th ed.) Citation

J, Ma, et al. "Revisiting the Use of Capecitabine in the Era of Immunotherapy: Efficacy as Second-line and Later Therapy in Recurrent/metastatic Head and Neck Squamous Cell Carcinoma." Oral Oncology, vol. 164, 2025, p. 107293, https://doi.org/10.1016/j.oraloncology.2025.107293.